Cerner closed the most recent trading day at $91.20, moving -0.21% from the previous trading session. This move lagged the S&P 500's daily gain of 1.89%. Meanwhile, the Dow gained 1.17%, and the Nasdaq, a tech-heavy index, added 0.75%.
Heading into today, shares of the health care information technology company had lost 1.59% over the past month, outpacing the Medical sector's loss of 10.76% and the S&P 500's loss of 7.36% in that time.
Wall Street will be looking for positivity from Cerner as it approaches its next earnings report date. The company is expected to report EPS of $0.88, up 12.82% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $1.49 billion, up 6.53% from the year-ago period.
Any recent changes to analyst estimates for Cerner should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Cerner is currently sporting a Zacks Rank of #2 (Buy).
Valuation is also important, so investors should note that Cerner has a Forward P/E ratio of 24.82 right now. Its industry sports an average Forward P/E of 20.84, so we one might conclude that Cerner is trading at a premium comparatively.
It is also worth noting that CERN currently has a PEG ratio of 1.94. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. CERN's industry had an average PEG ratio of 1.82 as of yesterday's close.
The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 96, which puts it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Cerner closed the most recent trading day at $91.20, moving -0.21% from the previous trading session. This move lagged the S&P 500's daily gain of 1.89%. Meanwhile, the Dow gained 1.17%, and the Nasdaq, a tech-heavy index, added 0.75%.
Heading into today, shares of the health care information technology company had lost 1.59% over the past month, outpacing the Medical sector's loss of 10.76% and the S&P 500's loss of 7.36% in that time.
Wall Street will be looking for positivity from Cerner as it approaches its next earnings report date. The company is expected to report EPS of $0.88, up 12.82% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $1.49 billion, up 6.53% from the year-ago period.
Any recent changes to analyst estimates for Cerner should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Cerner is currently sporting a Zacks Rank of #2 (Buy).
Valuation is also important, so investors should note that Cerner has a Forward P/E ratio of 24.82 right now. Its industry sports an average Forward P/E of 20.84, so we one might conclude that Cerner is trading at a premium comparatively.
It is also worth noting that CERN currently has a PEG ratio of 1.94. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. CERN's industry had an average PEG ratio of 1.82 as of yesterday's close.
The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 96, which puts it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>